Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity

被引:124
作者
Domanski, TL [1 ]
He, YA [1 ]
Khan, KK [1 ]
Roussel, F [1 ]
Wang, QM [1 ]
Halpert, JR [1 ]
机构
[1] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
关键词
D O I
10.1021/bi010758a
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phenylalanine and/or tryptophan scanning mutagenesis was performed at 15 sites within CYP3A4 proposed to be involved in substrate specificity or cooperativity. The sites were chosen on the basis of previous studies or from a comparison with the structure of P450(eryF) containing two molecules of androstenedione. The function of the 25 mutants was assessed in a reconstituted system using progesterone, testosterone, 7-benzyloxy-4-(trifluoromethyl)coumarin (7-BFC), and alpha -naphthoflavone (ANF) as substrates. CYP3A4 wild type displayed sigmoidal kinetics of ANF 5,6-oxide formation and 7-BFC debenzylation. Analysis of 12 mutants with significant steroid hydroxylase activity showed a lack of positive correlation between ANF oxidation and stimulation of progesterone 6 beta -hydroxylation by ANF, indicating that ANF binds at two sites within CYP3A4. 7-BFC debenzylation was stimulated by progesterone and ANF, and 7-BFC did not inhibit testosterone or progesterone 6 beta -hydroxylation. Correlational analysis showed no relationship between 7-BFC debenzylation and either progesterone or testosterone 6 beta -hydroxylation. These data are difficult to explain with a two-site model of CYP3A4 but suggest that three subpockets exist within the active site. Interestingly, classification of the mutants according to their ability to oxidize the four substrates utilized in this study suggested that substrates do bind at preferred locations in the CYP3A4 binding pocket.
引用
收藏
页码:10150 / 10160
页数:11
相关论文
共 44 条
  • [1] DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) : 131 - 137
  • [2] BUTERS JTM, 1994, DRUG METAB DISPOS, V22, P688
  • [3] Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity
    Cupp-Vickery, J
    Anderson, R
    Hatziris, Z
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3050 - 3055
  • [4] Domanski TL, 1999, J PHARMACOL EXP THER, V290, P1141
  • [5] Domanski TL, 2000, J PHARMACOL EXP THER, V293, P585
  • [6] Analysis of four residues within substrate recognition site 4 of human cytochrome p450 3A4:: Role in steroid hydroxylase activity and α-naphthoflavone stimulation
    Domanski, TL
    Liu, JP
    Harlow, GR
    Halpert, JR
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 350 (02) : 223 - 232
  • [7] DOMANSKI TL, 2001, IN PRESS CURR DRUG M
  • [8] Ekins S, 1998, INT J CLIN PHARM TH, V36, P642
  • [9] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491
  • [10] Fuhr U, 1996, INT J CLIN PHARM TH, V34, P139